Please login to the form below

Not currently logged in
Email:
Password:

Aragon Pharma

This page shows the latest Aragon Pharma news and features for those working in and with pharma, biotech and healthcare.

J&J’s Erleada first US drug for non-metastatic prostate cancer

J&J’s Erleada first US drug for non-metastatic prostate cancer

J&J acquired Erleada when it took over Aragon Pharma in 2013 in a deal valued at $1bn.

Latest news

  • J&J completes Aragon deal as Seragon is born J&J completes Aragon deal as Seragon is born

    The deal secures a promising new prostate cancer therapy for the pharma major in the form of Aragon's ARN-509, a second generation androgen receptor signalling inhibitor which has reached ... Seragon spun out. The closure of the deal also sees the

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics